135 related articles for article (PubMed ID: 20381611)
1. Proteomic analysis of Escherichia coli with experimentally induced resistance to piperacillin/tazobactam.
dos Santos KV; Diniz CG; Veloso Lde C; de Andrade HM; Giusta Mda S; Pires Sda F; Santos AV; Apolônio AC; de Carvalho MA; Farias Lde M
Res Microbiol; 2010 May; 161(4):268-75. PubMed ID: 20381611
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
[TBL] [Abstract][Full Text] [Related]
3. Proteomic changes in Bacteroides fragilis exposed to subinhibitory concentration of piperacillin/tazobactam.
Veloso Lde C; dos Santos KV; de Andrade HM; Pires Sda F; dos Santos SG; Vaz Trindade MJ; de Farias Lde M; de Carvalho MA
Anaerobe; 2013 Aug; 22():69-76. PubMed ID: 23618673
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
5. Rapid identification of protein biomarkers of Escherichia coli O157:H7 by matrix-assisted laser desorption ionization-time-of-flight-time-of-flight mass spectrometry and top-down proteomics.
Fagerquist CK; Garbus BR; Miller WG; Williams KE; Yee E; Bates AH; Boyle S; Harden LA; Cooley MB; Mandrell RE
Anal Chem; 2010 Apr; 82(7):2717-25. PubMed ID: 20232878
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of nalidixic acid resistance in Escherichia coli: identification and functional characterization of OM proteins.
Lin XM; Li H; Wang C; Peng XX
J Proteome Res; 2008 Jun; 7(6):2399-405. PubMed ID: 18438992
[TBL] [Abstract][Full Text] [Related]
7. Identification and antibody-therapeutic targeting of chloramphenicol-resistant outer membrane proteins in Escherichia coli.
Li H; Lin XM; Wang SY; Peng XX
J Proteome Res; 2007 Sep; 6(9):3628-36. PubMed ID: 17711325
[TBL] [Abstract][Full Text] [Related]
8. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
9. Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.
Thomson KS; Black J; Moland ES; Reuben J; Wiles T; Brasso W
Int J Antimicrob Agents; 2008 Jan; 31(1):83-5. PubMed ID: 17996426
[No Abstract] [Full Text] [Related]
10. Proteomic identification of the Cus system as a major determinant of constitutive Escherichia coli silver resistance of chromosomal origin.
Lok CN; Ho CM; Chen R; Tam PK; Chiu JF; Che CM
J Proteome Res; 2008 Jun; 7(6):2351-6. PubMed ID: 18419149
[TBL] [Abstract][Full Text] [Related]
11. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
12. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
13. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
London N; Thomson CJ; Amyes SG; Stobberingh E
FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
[TBL] [Abstract][Full Text] [Related]
14. Role of the culture medium in porin expression and piperacillin-tazobactam susceptibility in Escherichia coli.
Pinet E; Franceschi C; Davin-Regli A; Zambardi G; Pagès JM
J Med Microbiol; 2015 Nov; 64(11):1305-1314. PubMed ID: 26242994
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of experimentally induced azole resistance in Candida glabrata.
Rogers PD; Vermitsky JP; Edlind TD; Hilliard GM
J Antimicrob Chemother; 2006 Aug; 58(2):434-8. PubMed ID: 16735426
[TBL] [Abstract][Full Text] [Related]
16. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility survey of piperacillin/tazobactam and some beta-lactam comparators in Italy.
Stefani S; Bonfiglio G; Bianchi C; Zollo A; Nicoletti G
Drugs Exp Clin Res; 1998; 24(2):105-13. PubMed ID: 9675551
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin.
Pieper R; Gatlin-Bunai CL; Mongodin EF; Parmar PP; Huang ST; Clark DJ; Fleischmann RD; Gill SR; Peterson SN
Proteomics; 2006 Aug; 6(15):4246-58. PubMed ID: 16826566
[TBL] [Abstract][Full Text] [Related]
20. A multicentre in vitro evaluation of piperacillin/tazobactam in Germany.
Grimm H
Eur J Surg Suppl; 1994; (573):25-9. PubMed ID: 7524792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
